Epilepsy in patients with Angelman syndrome
Tóm tắt
Angelman syndrome (AS) is a neuro-behavioural, genetically determined condition, characterized by ataxic jerky movements, happy sociable disposition and unprovoked bouts of laughter in association with seizures, learning disabilities and language impairment. Most of the cases are hardly diagnosed during infancy as jerky movements, the cardinal sign, appear later in childhood. AS is caused by a variety of genetic mechanisms involving the 15q 11-13 chromosome. About 70% of cases are due to a "de novo" interstitial deletion in the long arm region, arising on the maternally inherited chromosome. The diagnosis is confirmed by methylation test or by mutation analysis of UBE3A gene. The deletion phenotype is generally linked to a more severe clinical picture in that 95% of patients manifest more severe seizures, severe mental and motor retardation, dysmorphic features and microcephaly. The pathogenesis of epilepsy in AS is still not fully understood. The presence in the commonly deleted region of a cluster of genes coding for 3 subunits of the GABAa receptor complex has lead to the hypothesis that GABA neurotransmission is involved. Epilepsy, often severe and hard to control, is present in 85% of patients within the first three years of life, although less than 25% develop seizures during the first year. It was observed that febrile seizures often precede the diagnosis. Most frequent types are atypical absences, generalized tonic-clonic, atonic or myoclonic seizures, with multiple seizure types occurring in 50% of deleted patients. There is still some doubt about the association with West syndrome. The EEG abnormalities are not themselves pathognomonic of AS and both background activity and epileptic discharges vary even in the same patient with time. Nevertheless, the existence of some suggestive patterns should facilitate the early diagnosis allowing the correct genetic counselling for the family. Some drugs seems to act better than others, Valproate, ethosuximide and clonazepam giving the best results.
Tài liệu tham khảo
Angelman H: "Puppet children" a report of three cases. Dev Med Child Neurol. 1965, 7: 681-688.
Robb SA, Pohl KRE, Baraitser M, Wilson J, Brett EM: The "happy puppet" syndrome of Angelman: review of the clinical features. Arch Dis Child. 1989, 64: 83-86. 10.1136/adc.64.1.83.
Clayton-Smith J, Driscoll DJ, Waters MF, Webb T, Andrews T, Pembrey ME, Malcom S, Nicholls RD: Differences in methylation pattern within the D15S9 region of chromosome 15q11-q13 in first cousins with Angelman and Prader Willi syndromes. Am J Med Genet. 1993, 47: 683-686. 10.1002/ajmg.1320470519.
Williams CA: Angelman Syndrome. Management of Genetic Syndromes. Edited by: Cassidy SB, Allanson JE. 2005, Wiley-Liss Inch, 53-62. 2
Knoll JHM, Nicholls RD, Magenis RE, Graham JM, Lalande M, Latt SA: Angelman and Prader Willi syndromes share a common chromosome 15 deletion but differ in parental origin of the deletion. Am J Med Genet. 1989, 32: 285-290. 10.1002/ajmg.1320320235.
Malcom S, Clayton-Smith J, Nichols M, Robb S, Webb T, Armour JAL, Jeffreys AJ, Pembrey ME: Uniparental paternal disomy in Angelman's syndrome. Lancet. 1991, 337: 694-697. 10.1016/0140-6736(91)90278-W.
Buiting K, Saitoh S, Gross S, Schwartz S, Nicholls RD, Horsthemke B: Inherited microdeletions in Angelman and Prader-Willi syndromes define an imprinting centre on human chromosome 15. Nat Genet. 1995, 9: 395-400. 10.1038/ng0495-395.
Kishino T, Lalande M, Wagstaff J: UBE3A/E6-AP mutations cause Angelmann Syndrome. Nat Genet. 1997, 15: 70-73. 10.1038/ng0197-70.
Matsuura T, Sutcliffe JS, Fang P, Galjaard RJ, Jiang YH, Benton CS, Rommens JM, Beaudet AL: De novo truncating mutations in E6-AP ubiquitin-protein ligase (UBE3A) in Angelman syndrome. Nature Genet. 1997, 15: 74-77. 10.1038/ng0197-74.
Rougelle C, Glatt H, Lalande M: The Angelman syndrome candidate gene UBE3A/E6AP is imprinted in brain. Nat Genet. 1997, 17: 14-15. 10.1038/ng0997-14.
Lossie AC, Whitney MM, Amidon D, Dong HJ, Chen P, Theriaque D, Hutson A, Nicholls RD, Zori RT, Williams CA, Driscoll DJ: Distinct phenotypes distinguish the molecular classes of Angelman syndrome. J Med Genet. 2001, 38: 834-835. 10.1136/jmg.38.12.834.
Minassian BA, DeLorey TM, Olsen RW, Philippart M, Bronstein Y, Zhang Q, Guerrini R, Van Ness P, Livet MO, Delgado-Escueta AV: Angelman Syndrome: correlations between epilepsy phenotypes and genotypes. Ann Neurol. 1998, 43: 485-493. 10.1002/ana.410430412.
Nicholls RD, Saitoh S, Horsthemke B: Imprinting in Prader-Willi and Angelman syndromes. Trends Genet. 1998, 14: 194-200. 10.1016/S0168-9525(98)01432-2.
Dan B, Boyd SG: Angelman syndrome reviewed from a neurophysiological perspective. The UBE3A-GABRB3 hypothesis. Neuropediatrics. 2003, 34: 169-176. 10.1055/s-2003-42213.
Dan B: Angelman syndrome: Current understanding and research prospects. Epilepsia. 2009, 50 (11): 2331-2339. 10.1111/j.1528-1167.2009.02311.x.
Samaco RC, Hogart A, LaSalle JM: Epigenetic overlap in autism-spectrum neurodevelopmental disorders: MECP2 deficiency causes reduced expression of UBE3A and GABRB3. Hum Mol Genet. 2005, 14 (4): 483-92. 10.1093/hmg/ddi045.
Clayton-Smith J: Clinical research on Angelman syndrome in the United Kingdom: observation on 82 affected individuals. Am J Med Genet. 1993, 46: 12-15. 10.1002/ajmg.1320460105.
Saitoh S, Harada N, Jinno Y, Hashimoto K, Imaizumi K, Kuroki Y, Fukushima Y, Sugimoto T, Renedo M, Wagstaff J, Lalande M, Mutirangura A, Kuwano A, Ledbetter DH, Nikawa N: Molecular and clinical study of 61 Angelman syndrome patients. Am J Med Genet. 1994, 52: 158-163. 10.1002/ajmg.1320520207.
Matsumoto A, Kumagai T, Miura K, Myazaki S, Hayakawa C, Yamanaka T: Epilepsy in Angelman syndrome associated with chromosome 15q deletion. Epilepsia. 1992, 33 (6): 1083-1090. 10.1111/j.1528-1157.1992.tb01763.x.
Viani F, Romeo A, Viri M, Mastrangelo M, Lalatta F, Selicorni A, Gobbi G, Lanzi G, Bettio D, Briscioli V: Seizures and EEG pattern in Angelman syndrome. J Chid Neurol. 1995, 10 (6): 467-471. 10.1177/088307389501000609.
Guerrini R, Carrozzo R, Rinaldi R, Bonanni P: Angelman syndrome: etiology, clinical features, diagnosis, and management of symptoms. Paediatr Drugs. 2003, 5 (10): 647-661. 10.2165/00148581-200305100-00001.
Valente KD, Koiffmann CP, Fridman C, Varella M, Kok F, Andrade JQ, Grossmann RM, Marques-Dias MJ: Epilepsy in patients with Angelman syndrome caused by deletion of the chromosome 15q11-q13. Arch Neurol. 2006, 63: 122-128. 10.1001/archneur.63.1.122.
Buoni S, Grosso S, Pucci L, Fois A: Diagnosis of Angelman syndrome: clinical and EEG criteria. Brain Dev. 1999, 21: 296-302. 10.1016/S0387-7604(99)00007-8.
Galvan-Manso M, Campistol J, Conill J, Sanmartì FX: Analysis of the characteristics of epilepsy in 37 patients with the molecular diagnosis of Angelman syndrome. Epileptic Disord. 2005, 7 (1): 19-25.
Pelc K, Boyd SG, Cheron G, Dan B: Epilepsy in Angelman syndrome. Seizure. 2008, 17: 211-217. 10.1016/j.seizure.2007.08.004.
Elia M: Myoclonic status in nonprogressive envephalopathies: an update. Epilepsia. 2009, 50 (suppl.5): 41-44. 10.1111/j.1528-1167.2009.02119.x.
Valente KD: Another Rett patient with a Typical Angelman EEG. Epilepsia. 2003, 44 (6): 873-874. 10.1046/j.1528-1157.2003.04803_3.x.
Boyd SG, Harden A, Patton MA: The EEG in early diagnosis of Angelman syndrome. Eur J Pediatr. 1988, 147: 508-513. 10.1007/BF00441976.
Laan LAEM, Vein AA: Angelman syndrome: is there a characteristic EEG?. Brain Develop. 2005, 27: 80-87. 10.1016/j.braindev.2003.09.013.
Valente KDF, Andrade JQ, Grossmann RM, Kok F, Fridman C, Koiffman CP, Marques-Dias MJ: Angelman syndrome: difficulties in EEG pattern recognition and possible misinterpretations. Epilepsia. 2003, 44 (8): 1051-1063. 10.1046/j.1528-1157.2003.66502.x.
Ostergaard JR, Balslev T: Efficacy of different antiepileptic drugs in children with Angelman syndrome associated with 15q11-13 deletion: the Danish experience. Dev Med Child Neurol. 2001, 43: 718-719. 10.1017/S0012162201001293.
Franz DN, Glauser TA, Tudor C, Williams S: Topiramate therapy of epilepsy associated with Angelman syndrome. Neurology. 2000, 54: 1185-1188.
Sugiura C, Ogura K, Ueno M, Toyoshima M, Oka A: High dose ethosuximide for epilepsy in Angelman syndrome: implication of GABA(A) receptor subunit. Neurology. 2001, 57: 1518-1519.
Dion MH, Novotny EJ, Carmant L, Cossette P, Nguyen DK: Lamotrigine therapy of epilepsy with Angelman syndrome. Epilepsia. 2007, 48 (3): 593-596. 10.1111/j.1528-1167.2006.00969.x.
Forrest KML, Young H, Dale RC, Gill DS: Benefit of corticosteroid therapy in Angelman Syndrome. J Child Neurol. 2009, 24 (8): 952-958. 10.1177/0883073808331344.
Pitt D, Hopkins I: A syndrome of mental retardation, wide mouth and intermittent overbreathing. Austr Ped J. 1978, 14: 182-184.
Rosenfeld JA, Leppig K, Ballif BC, Thiese H, Erdie-Lalena C, Bawle E, Sastry S, Spence JE, Bandholz A, Surti U, Zonana J, Keller K, Meschino W, Bejjani BA, Torchia BS, Shaffer LG: Genotype-phenotype analysis of TCF4 mutations causing Pitt-Hopkins syndrome shows increased seizure activity with missense mutations. Genet Med. 2009, 11 (11): 797-805. 10.1097/GIM.0b013e3181bd38a9.
Laan LAEM, Renier WO, Arts WFM, Buntinx IM, vd Burgt IJAM, Stroink H, Beuten J, Zwinderman KH: Evolution of epilepsy and EEG findings in Angelman syndrome. Epilepsia. 1997, 38: 195-199. 10.1111/j.1528-1157.1997.tb01097.x.